October 14, 2019 03:47 PM IST Net Sales are expected to increase by 18.8 percent Y-o-Y (up 3.7 percent Q-o-Q) to Rs. 5,645.7 crore, according to Emkay.
April 17, 2019 03:10 PM IST Net Sales are expected to increase by 26.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 5,121.6 crore, according to Kotak.
April 12, 2019 12:45 PM IST Net Sales are expected to increase by 25.9 percent Y-o-Y (down 3 percent Q-o-Q) to Rs. 5,020.7 crore, according to Prabhudas Lilladher.
February 11, 2019 01:08 PM IST Aurobindo has maintained its guidance of 30 percent YoY growth in injectable sales. Further, company filed 10 ANDAs, including 4 injectables, taking the cumulative ANDAs pending for approval to 122
February 07, 2019 07:54 AM IST The company will declare its results today. Analysts suggest one to focus on US business growth and upcoming product announcements.
January 18, 2019 01:51 PM IST Net Sales are expected to increase by 12.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 4,888 crore, according to Sharekhan.
January 11, 2019 05:23 PM IST Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.
January 04, 2019 10:45 AM IST For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
November 12, 2018 08:18 AM IST Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.
October 17, 2018 05:39 PM IST Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.
October 16, 2018 06:55 PM IST Net Sales are expected to increase by 6.3 percent Y-o-Y (up 10.9 percent Q-o-Q) to Rs. 4,714 crore, according to Sharekhan.
October 12, 2018 03:54 PM IST Net Sales are expected to increase by 4.6 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 4,638.9 crore, according to ICICI Direct.
August 25, 2018 10:26 AM IST Emkay Global, in its report, observed that cycling pressure in US market will start waning ahead, but structural pressures will still persist.
July 18, 2018 02:06 PM IST Net Sales are expected to increase by 12 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,119 crore, according to Kotak.
July 12, 2018 09:42 PM IST "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities
April 20, 2018 01:01 PM IST Net Sales are expected to increase by 13.8 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs. 4,100 crore, according to HDFC Securities.
April 16, 2018 05:55 PM IST Net Sales are expected to increase by 19 percent Y-o-Y to Rs. 4,334.4 crore, according to Edelweiss.
April 12, 2018 05:53 PM IST Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
February 07, 2018 12:28 PM IST Europe and Rest of World sales are likely to grow 15-18 percent YoY while API business is likely to be flat.
January 18, 2018 08:36 AM IST As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
January 11, 2018 04:06 PM IST The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.
November 08, 2017 05:26 PM IST EBITDA (earnings before interest, tax, depreciation and amortisation) may increase 15.6 percent year-on-year to Rs 1,074.4 crore and margin may expand 110 basis points to 25.7 percent for quarter ended September 2017.
October 13, 2017 05:31 PM IST Net Sales are expected to increase by 6.9 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 4035.4 crore, according to Kotak.
August 10, 2017 11:02 AM IST EU formulations contributed 25 percent to the total revenue registering a growth of 18.1 percent to a Rs.831 crore, led by an acquired business that has seen profitability during the year on the back of increased focus, product pruning and cost efficiencies.
April 17, 2017 01:08 PM IST Net Sales are expected to increase by 4.6 percent Q-o-Q (up 9.1 percent Y-o-Y) to Rs 4087.6 crore, according to ICICI Securities. Aurobindo to report net profit at 616.2 crore up 6.5% quarter-on-quarter.
